Viking's obesity drug study results are 'almost flawless', says Oppenheimer's Jay Olson
Jay Olson, Oppenheimer biotech analyst, joins 'Fast Money' to talk Viking's best trading day ever and the results of its obesity drug study.
Видео Viking's obesity drug study results are 'almost flawless', says Oppenheimer's Jay Olson канала CNBC Television
Видео Viking's obesity drug study results are 'almost flawless', says Oppenheimer's Jay Olson канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
U.S. mid-caps are a great diversifier, says John Hancock's Emily Roland
Retail investors are joining in on the 'Magnificent 7' hype
Opening Bell, November 4, 2022
High interest rates hit corporate investment in tech
Breaking down shares of Hilton, Expedia and Match Group
Three-Stock Lunch: Tidewater, Progressive & CRH PLC
'We expect moderation this year' in consumer spending, says NRF CEO Matt Shay
Lockheed Martin sees record order volume in 2022 as earnings beat estimates
Jim Lebenthal buys Adobe
CFRA's Sam Stovall: The projected S&P decline is due to the 10-year yield and inflation readings
CNBC's Investing Club on how to manage your portfolio so you stay diversified
M&A dealmaking landscape is showing signs of life, PwC report finds
Amazon replaces plastic packaging: Here's what to know
Clean Start: This clean-tech startup transforms carbon emissions into vodka
Citi's Scott Chronert on raising his year-end S&P 500 target to 5,600
Final Trades: Apple, Citigroup, Palantir & Amplify Mobile Payments ETF
Final Trades: Electronic Arts, Chevron, Adobe and Flex LNG
Moor Insights' Patrick Moorhead talks mega cap AI trades
Chart Master: Is a REIT revival incoming?
The market is due for a pause, says Freedom Capital's Jay Woods
Trade Tracker: Josh Brown buys NetApp